CONCERT PHARMACEUTICLS INC Physician/Doctor, Cardiologist …

The average salary for Physician/Doctor, Cardiologist (Non-Invasive) at companies like CONCERT PHARMACEUTICLS INC in the United States is $443,370 as of June 27, 2024, …

CouponFollow Extension

$443370
OFF

CONCERT PHARMACEUTICLS INC Physician/Doctor, Cardiologist …

1 week from now

The average salary for Physician/Doctor, Cardiologist (Non-Invasive) at companies like CONCERT PHARMACEUTICLS INC in the United States is $443,370 as of June 27, 2024, …

salary.com

$576
OFF

Sun Pharma To Acquire Concert Pharmaceuticals In $576

1 week from now

Jan 19, 2023 · Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share of common stock in …

cnbctv18.com

$65
OFF

Concert Pharma Stock Surges On $65M Financing From …

1 week from now

Nov 4, 2021 · Concert Pharmaceuticals Inc (NASDAQ: CNCE) has agreed with BVF Partners L.P. and RA Capital Management to raise gross proceeds of million. In addition, Concert will …

yahoo.com

FAQs about CONCERT PHARMACEUTICLS INC Physician/Doctor, Cardiologist … Coupon?

Who is Concert Pharmaceuticals?

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with Alopecia Areata, a serious autoimmune dermatological disease. ...

Who bought Concert Pharmaceuticals?

Concert Pharmaceuticals was acquired by Sun Pharmaceutical Industries for $576M on Jan 19, 2023. This deal was done in Cash. Which industries do these Sub-Organization operate in? ...

Will Sun Pharma acquire Concert Pharmaceuticals?

Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Sun Pharma will acquire all of the outstanding shares of Concert by way of a tender offer for an initial cash payment of 8.00 dollars per common share, or $576 million in net worth. ...

Why did Sun Pharma buy concert ophthalmology & dermatology?

“Sun Pharma is building a global Dermatology and Ophthalmology franchise and aims to be a preferred development and commercial partner in these therapies worldwide. The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma. ...

Are Sun Pharma & concert liable for any forward-looking statements?

Unless required by law, each of Sun Pharma and Concert is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this communication, whether as a result of new information, future events or otherwise. The tender offer referenced in this document has not yet commenced. ...

Does concert have a patent portfolio?

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development. ...